First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort
Based on meta-analysis of clinical trial data, first-line treatment of advanced Merkel cell carcinoma with ipilimumab plus nivolumab results in a higher objective response rate compared to monotherapy. The clinical decision to select combination therapy over monotherapy must weigh this response rate benefit with the unknown survival benefit and higher toxicity.
Authors
- Matthew Nichols
- Evan Wuthrick (ORCID: https://orcid.org/0000-0002-0838-9634)
- Joseph Markowitz (ORCID: https://orcid.org/0000-0003-2490-5464)
- Nikhil I. Khushalani (ORCID: https://orcid.org/0000-0002-3636-4143)
- Tanya Ramadoss
- Lilit Karapetyan (ORCID: https://orcid.org/0000-0001-8530-0907)
- Christian Palacios
- Ahmad A. Tarhini
- Kenneth Y Tsai
- Andrew S. Brohl
- Vernon K. Sondak
- Zeynep Eroglu
Institutions
- Nova Southeastern University (US)
- Moffitt Cancer Center (US)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1007/s00262-026-04313-2
- Primary Topic
- Polyomavirus and related diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00